Search

Generalized pustular psoriasis (GPP) is a severe and uncommon form of psoriasis, for which treatment options are limited. There is an urgent need to expand the treatment options for GPP. Currently, adalimumab, secukinumab, and guselkumab are considered effective for GPP, but there is a lack of prospective direct comparative studies on their efficacy for GPP. We conducted a prospective, single-center, observational study on 50 GPP patients to compare the efficacy, safety, and recurrence rates of these three biologics. Adalimumab, secukinumab, and guselkumab resulted in varying degrees of improvement in patients with GPP, but guselkumab exhibited superior efficacy and a lower recurrence rate than the other two drugs. This enhanced response may be attributed to the significant reduction in CD8+ tissue-resident memory T cells within GPP lesions caused by guselkumab. • After 12 weeks of treatment, guselkumab had a better response rate than adalimumab and secukinumab. • Guselkumab was associated with a lower recurrence rate and a longer time to relapse. • The number of TRM cells was higher in GPP skin lesions than in normal control lesions, and the number of CD8 + TRM cells was decreased significantly in the dermis and epidermis after guselkumab treatment. [ABSTRACT FROM AUTHOR]